Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases including COPD and asthma, has announced a $75 million oversubscribed Series B funding round led by Forbion, with participation from Sanofi and Altesa's existing investors, including Medicxi, Pitango, and Atlantic Partners.

Altesa BioSciences is a clinical-stage pharmaceutical company, led by global experts in respiratory medicine and infectious diseases. Altesa is dedicated to improving the lives of people with chronic lung diseases, like COPD and asthma, by treating the principal cause of exacerbations and pathological inflammation - viral respiratory infections. In addition to advancing vapendavir, their lead medicine, Altesa advocates for improved access to modern respiratory diagnostics and therapeutics in underserved communities.